Current stock page

Catalysts

WVE Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Sep 4, 2026

WVE

Catalysts
Wave Life Sciences Ltd.
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 2/10
Low Priority
Relative Laggard
Score data as of Sep 4, 2026
Last price
$4.86
+$0.16 (+3.40%)
Latest market quote
Momentum36
Value34
Quality59
Risk Resilience38
Sentiment
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 9, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 43/100

Momentum 36/100 and sentiment before the next covered event.

Recent coverage
5 articles

Updated Sep 6, 2026 · Sentiment 26.03%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 36/100AIQ Edge 2/10 Relative Laggard
Beat rate
25%
2 of 8 reported periods
Average surprise
+19.0%
Across covered historical reports
Latest result
-13.4%
Jul 30, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Jul 30, 2026-$0.30-$0.34-13.4%$7.45M$2.27M
Apr 28, 2026-$0.34-$0.13+61.8%$8.45M$38.25M
Feb 26, 2026-$0.28-$0.30-7.1%$16.06M$17.24M
Nov 10, 2025-$0.30-$0.32-6.7%$16.35M$7.61M
Jul 30, 2025-$0.29-$0.31-6.9%$9.85M$8.7M
May 8, 2025-$0.27-$0.29-7.4%$14.42M$9.18M
Mar 4, 2025-$0.17$0.17+200.0%$12.17M$83.75M
Nov 12, 2024-$0.28-$0.47-67.9%$25.59M-$7.68M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
16
Buy
12-month analyst target
$14.33
+194.86% versus current price
Based on 7 analyst observations. Targets are estimates, not predictions.
Low target
$12.00
+146.91% vs latest price
Average target
$14.33
+194.86% vs latest price
High target
$18.00
+270.37% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 9, 2026

Next known earnings or reporting date.

EPS estimate-$0.33

Current analyst expectation for the upcoming report.

Revenue estimate$5.03M

Current analyst expectation for the upcoming report.

Sentiment score

News pressure around the setup.

Momentum score36

Where event reaction would show up first.

AIQ score43/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
7
Average target
$14.33
Target upside
194.86%
Target range
$12.00 - $18.00
90-day revisions
-51

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
seekingalpha.com · Aug 11, 2026

Wave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference Transcript

Wave Life Sciences Ltd. (WVE) Bank of America SMID Cap Virtual Conference August 11, 2026 1:00 PM EDTCompany ParticipantsPaul Bolno - President, CEO &...

seekingalpha.com · Jul 30, 2026

Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call Transcript

Wave Life Sciences Ltd. (WVE) Q2 2026 Earnings Call July 30, 2026 8:30 AM EDTCompany ParticipantsKate Rausch - Head of Investor RelationsPaul Bolno -...

manilatimes.net · Jul 23, 2026

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company’s second quarter 2026 financial results and provide business updates.

manilatimes.net · Jul 7, 2026

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health ('Wave” or 'Wave Life Sciences”), has obtained the requisite shareholder approval required in connection with its proposed redomiciliation ('Redomiciliation”) to the United States by way of the implementation of a statutory procedure known as a scheme of arrangement under Section 210 of the Companies Act 1967 of Singapore (the 'Scheme of Arrangement”). The Scheme of Arrangement remains subject to approval by the High Court of the Republic of Singapore (the 'Singapore Court”).

finance.yahoo.com · Jun 13, 2026

Is Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?

Is WVE a good stock to buy? We came across a bullish thesis on Wave Life Sciences Ltd. on Biotech Distilled’s Substack. In this article, we will summarize the bulls’ thesis on WVE. Wave Life Sciences Ltd.’s share was trading at $5.70 as of June 8th. Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and […]

Open full news and sentiment

WVE Catalysts FAQ

What are the next catalysts for WVE stock?

WVE's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move WVE stock?

Upcoming events that could move WVE include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could WVE's next earnings report affect the stock?

WVE's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive WVE stock higher?

WVE could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt WVE stock?

WVE could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.